Dr. Reddy's Laboratories (500124) Hisse Özeti
Dr. Reddy's Laboratories Limited, iştirakleri ile birlikte dünya çapında entegre bir ilaç şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 5/6 |
500124 Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Dr. Reddy's Laboratories Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹1,206.00 |
| 52 Haftanın En Yüksek Seviyesi | ₹1,414.40 |
| 52 Haftanın En Düşük Seviyesi | ₹1,080.05 |
| Beta | 0.24 |
| 1 Aylık Değişim | -3.19% |
| 3 Aylık Değişim | -9.79% |
| 1 Yıllık Değişim | -4.23% |
| 3 Yıllık Değişim | 2.55% |
| 5 Yıllık Değişim | 28.69% |
| Halka arzdan bu yana değişim | 35,328.86% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 06
500124: Fair Outlook Will Balance New Drug Launches And Compliance Developments
Analysts now place fair value for Dr. Reddy's Laboratories at about ₹1,266, compared with the prior estimate of roughly ₹1,332. The revision reflects updated assumptions for slightly higher revenue growth, a marginally lower discount rate and a more conservative future P/E multiple.
Anlatı Güncellemesi • Jul 23
500124: New Biologics And Diabetes Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories from ₹1,679 to about ₹1,600, citing updated assumptions that combine slightly higher projected revenue growth and profit margins with a lower future P/E multiple. What's in the News Dr. Reddy's Laboratories reported that the USFDA completed a Pre License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad, issuing a Form 483 with seven observations that the company plans to address within the required timeline.Recent updates
Anlatı Güncellemesi • Aug 06
500124: Fair Outlook Will Balance New Drug Launches And Compliance Developments
Analysts now place fair value for Dr. Reddy's Laboratories at about ₹1,266, compared with the prior estimate of roughly ₹1,332. The revision reflects updated assumptions for slightly higher revenue growth, a marginally lower discount rate and a more conservative future P/E multiple.Anlatı Güncellemesi • Jul 23
500124: New Biologics And Diabetes Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories from ₹1,679 to about ₹1,600, citing updated assumptions that combine slightly higher projected revenue growth and profit margins with a lower future P/E multiple. What's in the News Dr. Reddy's Laboratories reported that the USFDA completed a Pre License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad, issuing a Form 483 with seven observations that the company plans to address within the required timeline.
Anlatı Güncellemesi • Jun 25
500124: Lower Profitability Expectations Will Restrain Future Share Price Upside
Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.Anlatı Güncellemesi • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.Anlatı Güncellemesi • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Anlatı Güncellemesi • May 03
500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.Anlatı Güncellemesi • Apr 19
500124: Future Tax And Regulatory Compliance Issues Will Limit Upside Potential
Analysts have revised their price target for Dr. Reddy's Laboratories to ₹1,024, reflecting updated assumptions of higher revenue growth of 5.96%, a profit margin of 16.95% and a lower future P/E of 17.43x. What's in the News Launch of Obeda, an injectable semaglutide for type 2 diabetes in India, following Drugs Controller General of India approval for generic semaglutide.Anlatı Güncellemesi • Apr 05
500124: Fair Outlook Will Balance Biosimilar Opportunity And Compliance Developments
Analysts have increased their price target on Dr. Reddy's Laboratories by about ₹13 to ₹1,314, citing updated assumptions that include a different discount rate, revised revenue growth and profit margin estimates, and an adjusted future P/E multiple. What's in the News Board meeting scheduled for March 24, 2026, to amend the Code of Practices and Procedures for Fair Disclosures of Un published Price Sensitive Information, signaling a focus on disclosure norms and compliance (company filing).Anlatı Güncellemesi • Mar 21
500124: Biosimilar Pipeline Progress Will Drive Future Upside Despite GST Disputes
Analysts have maintained their price target for Dr. Reddy's Laboratories at ₹1,615. This reflects only minor adjustments to revenue growth, profit margin and forward P/E assumptions, rather than a change in the overall valuation view.Anlatı Güncellemesi • Mar 07
500124: Biosimilar Approvals Will Drive Future Upside Despite Regulatory And Tax Overhang
Analysts have kept their price target for Dr. Reddy's Laboratories unchanged at ₹1,615, citing only marginal tweaks to revenue growth, profit margin and forward P/E assumptions that do not materially alter their valuation view. What's in the News The USFDA has accepted review of Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept) for multiple autoimmune indications, supported by analytical, PK and clinical data, including an ongoing Phase 3 trial (company announcement).Anlatı Güncellemesi • Feb 21
500124: Biosimilar Pipeline And New Launches Will Drive Future Upside
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories slightly higher from about ₹1,611 to roughly ₹1,615 per share, reflecting updated assumptions on revenue growth, profit margins, and the future P/E multiple in their models. What's in the News US FDA accepted review of a 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to Orencia (abatacept), for multiple rheumatoid and arthritis indications in adults and children, backed by analytical, PK, and clinical data including Phase 1 PK similarity and an ongoing Phase 3 trial (company announcement).Anlatı Güncellemesi • Feb 07
500124: Future Regulatory And Tax Compliance Risks Will Limit Upside Potential
Analysts have raised their fair value estimate for Dr. Reddy's Laboratories from ₹990 to ₹1,024, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E as key drivers of this change. What's in the News Launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent to Extra Strength Pataday Once Daily Relief, for temporary relief of itchy eyes caused by allergens.Anlatı Güncellemesi • Jan 23
500124: Biosimilar Approvals And New Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories slightly from ₹1,615 to about ₹1,611, reflecting updated views on future revenue growth, profit margins, and a higher assumed future P/E multiple. What's in the News Launched an over the counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent of Extra strength Pataday Once Daily Relief, targeting temporary relief of itchy eyes from allergens such as pollen, grass and animal dander (USFDA approval).Anlatı Güncellemesi • Jan 06
500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.Anlatı Güncellemesi • Dec 14
500124: Biosimilar Approvals Will Drive Future Upside Despite Slight Multiple Compression
Analysts have marginally lowered their price target on Dr. Reddy's Laboratories to ₹1,615 from ₹1,626, reflecting a slightly higher discount rate, while also factoring in stronger revenue growth, improved profit margins and a somewhat lower future P E multiple. What's in the News European Commission grants marketing authorization for AVT03, Dr. Reddy's and Alvotech's biosimilar to Prolia and Xgeva, with Dr. Reddy's holding exclusive commercialization rights in the U.S. and semi exclusive rights in Europe and the UK (company announcement) EMA's CHMP earlier issued a positive opinion recommending AVT03 for marketing authorization across the European Economic Area, with a separate submission planned to the UK MHRA under the International Recognition Procedure (company announcement) Dr. Reddy's receives an Establishment Inspection Report from the USFDA, with the inspection classified as Voluntary Action Indicated and officially closed (regulatory filing) Eisai and Dr. Reddy's reach a patent settlement allowing Dr. Reddy's to launch a generic version of cancer drug Lenvima in the U.S. from July 1, 2030, subject to certain contingencies (legal filing) Company launches Tegoprazan in India under the brand name PCAB to treat acid related gastrointestinal diseases, targeting a large and growing acid peptic disease population (product launch) Valuation Changes The fair value estimate has been reduced slightly to ₹1,615 from ₹1,625.93, reflecting a modestly more conservative outlook.Anlatı Güncellemesi • Oct 27
Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities
Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.Anlatı Güncellemesi • Sep 04
Investments In Biosimilars And NRT Will Expand Market Reach, Yet Regulatory Hurdles May Persist
With both revenue growth and net profit margin forecasts steady, analysts maintained their fair value estimate for Dr. Reddy's Laboratories at ₹1287. What's in the News Dr. Reddy's Laboratories and Extrovis AG launched Fluorouracil Cream, 0.5% in the US as an authorized generic, approved by the USFDA.
Yeni Anlatı • Nov 13
Regulatory Hurdles And Rising Expenses Threaten To Squeeze Margins And Stifle Growth
Upfront costs from acquisitions and partnerships may pressure short-term earnings and compress net margins.Hissedar Getirileri
| 500124 | IN Pharmaceuticals | IN Pazar | |
|---|---|---|---|
| 7D | 2.6% | 0.9% | -0.08% |
| 1Y | -4.2% | 16.9% | 4.6% |
Getiri vs. Endüstri: 500124 geçen yıl % 16.9 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 500124 geçen yıl % 4.6 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| 500124 volatility | |
|---|---|
| 500124 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.6% |
İstikrarlı Hisse Senedi Fiyatı: 500124 son 3 ayda Indian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 500124 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1984 | 27,527 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, iştirakleri ile birlikte dünya çapında entegre bir ilaç şirketi olarak faaliyet göstermektedir. Global Jenerik, Farmasötik Hizmetler ve Etkin Maddeler (PSAI) ve Diğer segmentleri aracılığıyla faaliyet göstermektedir. Şirketin Global Jenerik segmenti, bir marka adı altında veya markalı formülasyonlara terapötik eşdeğerliğe sahip jenerik bitmiş dozajlar olarak pazarlanan reçeteli ve reçetesiz bitmiş farmasötik ürünler üretmekte ve pazarlamakta ve ayrıca biyolojik ürünler işiyle uğraşmaktadır.
Dr. Reddy's Laboratories Limited Temel Bilgiler Özeti
| 500124 temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹1.00t |
| Kazançlar(TTM) | ₹33.11b |
| Gelir(TTM) | ₹331.19b |
30.3x
F/K Oranı3.0x
P/S Oranı500124 aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| 500124 gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹331.19b |
| Gelir Maliyeti | ₹165.01b |
| Brüt Kâr | ₹166.18b |
| Diğer Giderler | ₹133.07b |
| Kazançlar | ₹33.11b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 39.75 |
| Brüt Marj | 50.18% |
| Net Kâr Marjı | 10.00% |
| Borç/Özkaynak Oranı | 14.9% |
500124 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.7%
Mevcut Temettü Verimi20%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/13 19:14 |
| Gün Sonu Hisse Fiyatı | 2026/08/13 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Dr. Reddy's Laboratories Limited 75 Bu analistlerden 38, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Umesh Laddha | Ambit Capital |
| Gaurav Tinani | Ambit Capital |